Literature DB >> 16342528

Characterization of the use of antiemetic agents in dogs with parvoviral enteritis treated at a veterinary teaching hospital: 77 cases (1997-2000).

Nina L Mantione1, Cynthia M Otto.   

Abstract

OBJECTIVE: To characterize the use of antiemetic agents in dogs with canine parvovirus (CPV)-associated enteritis in a veterinary teaching hospital.
DESIGN: Retrospective case series. ANIMALS: 77 dogs with CPV-associated enteritis. PROCEDURE: Medical records of 560 dogs with confirmed CPV-associated enteritis that were admitted to a veterinary teaching hospital were reviewed. Exclusion criteria included vaccination against CPV infection within the preceding 2 weeks, hospitalization for < 24 hours or removal from the hospital against advice, or an incomplete record. Signalment, duration of hospitalization, and daily antiemetic administrations were assessed; WBC counts and clinical findings were used to classify dogs as having systemic inflammatory response syndrome (SIRS).
RESULTS: 77 dogs were included in the study; 55 (71%) received antiemetics (53 received metoclopramide at least once). Seventy-one dogs survived, and 6 dogs died (all 6 received antiemetics). Compared with dogs that did not receive antiemetics, duration of hospitalization was significantly longer for antiemetic-treated dogs. Daily values of rectal temperature and heart and respiratory rates did not predict administration of antiemetics or duration of hospitalization; however, compared with survivors, SIRS developed more frequently among nonsurvivors. Assessment of emetic events recorded hourly for 17 dogs indicated that antiemetic treatment did not control emesis. CONCLUSIONS AND CLINICAL RELEVANCE: Many dogs with CPV-associated enteritis had persistent vomiting despite antiemetic administration. The apparent difference in duration of hospitalization between antiemetic-treated dogs and other dogs may reflect a difference in disease severity between groups, although antiemetic-associated adverse events (e.g., signs of depression, hypotension, and immune modulation) may prolong hospitalization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16342528     DOI: 10.2460/javma.2005.227.1787

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  6 in total

Review 1.  Canine parvoviral enteritis: an update on the clinical diagnosis, treatment, and prevention.

Authors:  Mathios E Mylonakis; Iris Kalli; Timoleon S Rallis
Journal:  Vet Med (Auckl)       Date:  2016-07-11

2.  Changes in salivary analytes in canine parvovirus: A high-resolution quantitative proteomic study.

Authors:  Lorena Franco-Martínez; Asta Tvarijonaviciute; Anita Horvatić; Nicolas Guillemin; José Joaquín Cerón; Damián Escribano; David Eckersall; Meriç Kocatürk; Zeki Yilmaz; Elsa Lamy; Silvia Martínez-Subiela; Vladimir Mrljak
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2018-09-24       Impact factor: 2.268

3.  Comparative efficacy of metoclopramide, ondansetron and maropitant in preventing parvoviral enteritis-induced emesis in dogs.

Authors:  E Yalcin; G O Keser
Journal:  J Vet Pharmacol Ther       Date:  2017-02-14       Impact factor: 1.786

4.  A retrospective study of 237 dogs hospitalized with suspected acute hemorrhagic diarrhea syndrome: Disease severity, treatment, and outcome.

Authors:  Nana Dupont; Lisbeth Rem Jessen; Frida Moberg; Nathali Zyskind; Camilla Lorentzen; Charlotte Reinhard Bjørnvad
Journal:  J Vet Intern Med       Date:  2021-02-27       Impact factor: 3.333

Review 5.  Update on Canine Parvoviral Enteritis.

Authors:  Elisa M Mazzaferro
Journal:  Vet Clin North Am Small Anim Pract       Date:  2020-09-02       Impact factor: 2.093

6.  Parvovirus enteritis and other risk factors associated with persistent gastrointestinal signs in dogs later in life: a retrospective cohort study.

Authors:  Kanae Sato-Takada; Anne M Flemming; Maarten J Voordouw; Anthony P Carr
Journal:  BMC Vet Res       Date:  2022-03-11       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.